Workflow
EQB to announce fourth quarter and fiscal 2025 results
Prnewswire· 2025-11-05 16:58
Accessibility StatementSkip Navigation TORONTO, Nov. 5, 2025 /PRNewswire/ - EQB Inc. (TSX: EQB) will report its fourth quarter and fiscal 2025 financial results after market close on December 3, 2025, and will host an earnings conference call on December 4, 2025, at 10:30 a.m. ET. EQB's Chadwick Westlake, President and Chief Executive Officer, Anilisa Sainani, Chief Financial Officer, and Marlene Lenarduzzi, Chief Risk Officer, will host the listen-only conference call and webcast. The details of the call/w ...
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
Seeking Alpha· 2025-11-05 16:57
Analyst’s Disclosure:I/we have a beneficial long position in the shares of SNDX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers a ...
Kinross Gold Q3 earnings beat on higher gold price, analysts boost target
Proactiveinvestors NA· 2025-11-05 16:57
About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday - Babcock & Wilcox (NYSE:BW), Digital Turbine (NASDAQ:APPS)
Benzinga· 2025-11-05 16:56
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Wednesday.Shares of Johnson Controls International PLC (NYSE:JCI) rose sharply during Wednesday's session after the company reported fourth-quarter results that topped analyst estimates on both earnings and revenue.The company reported fourth-quarter adjusted earnings per share of $1.26, beating the analyst consensus estimate of $1.20. Quarterly revenue came in at $6.44 billion, topping the Street's $6.32 billion forecast.Joh ...
TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up
ZACKS· 2025-11-05 16:56
Key Takeaways Bio-Techne posted Q1 EPS of 42 cents, matching estimates and flat year over year.TECH revenues fell 1% to $286.6 million, missing expectations and triggering a 7.5% stock drop. TECH's gross and operating margins expanded, supported by lower costs and stable segment performance. Bio-Techne Corporation (TECH) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 42 cents, which matched the Zacks Consensus Estimate. The bottom line remained flat on a year-over-year basis. The qu ...
Standard Motor Q3 Earnings Top Estimates, Guidance Revised
ZACKS· 2025-11-05 16:56
Key Takeaways SMP posted Q3 EPS of $1.36, above estimates and up from $1.28 a year earlier.Revenues rose to $499 million, driven by strong Temperature Control segment sales.2025 sales growth guidance raised to low-to-mid 20s%, with higher EBITDA margin outlook.Standard Motor Products (SMP) posted third-quarter 2025 adjusted earnings per share (EPS) of $1.36, which surpassed the Zacks Consensus Estimate of $1.14 and rose from $1.28 reported in the prior-year quarter.Total revenues rose to $499 million from $ ...
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
ZACKS· 2025-11-05 16:56
Key Takeaways Exelixis' Q3 earnings of $0.78 per share topped estimates and rose from $0.47 a year ago.Revenues grew 10.8% to $598M, driven by higher Cabometyx sales and strong product demand.EXEL narrows 2025 revenue outlook to $2.30-$2.35B and expands its stock repurchase program.Exelixis, Inc. (EXEL) reported better-than-expected results for the third quarter of 2025.Adjusted earnings of 78 cents per share beat the Zacks Consensus Estimate of 68 cents. The company registered adjusted earnings of 47 cents ...
Sempra Energy's Q3 Earnings Top Estimates, Revenues Increase Y/Y
ZACKS· 2025-11-05 16:56
Key Takeaways Sempra Energy's Q3 adjusted EPS of $1.11 beat estimates by 19.4% and rose 24.7% year over year.Revenues grew 13.3% to $3.15 billion, led by stronger results in Sempra California operations.SRE reaffirmed 2025 EPS guidance of $4.30-$4.70 and maintained its long-term growth outlook.Sempra Energy (SRE) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.11, which beat the Zacks Consensus Estimate of 93 cents by 19.4%. The bottom line also increased 24.7% from year-ago quarter’s fi ...
Flowers Foods Set to Release Q3 Earnings: Key Insights for Investors
ZACKS· 2025-11-05 16:56
Key Takeaways Flowers Foods' Q3 revenues are estimated at $1.23B, up 3.6% from the prior-year quarter.Earnings are projected at 23 cents per share, down 30.3% year over year.Product innovation and portfolio shifts are helping support overall business resilience.Flowers Foods, Inc. ((FLO) is likely to register top-line growth when it reports third-quarter 2025 earnings on Nov. 6. The Zacks Consensus Estimate for revenues is pegged at $1.23 billion, which indicates an increase of 3.6% from the figure reported ...
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y
ZACKS· 2025-11-05 16:56
Key Takeaways FMS posted Q3 EPS of $0.64, topping estimates and rising 35.8% year over year.FMS' revenues grew 2.6% to $5.71B, lifted by 10% organic growth despite divestitures and currency headwinds.FMS' gross margin rose 130 bps to 25.4%, while operating income jumped 22.4% on cost savings and pricing gainsFresenius Medical Care AG & Co. (FMS) reported third-quarter 2025 adjusted earnings per share (EPS) of 64 cents, which surpassed the Zacks Consensus Estimate by 8.47%. The bottom line improved 35.8% yea ...